Annexon, Inc. (NASDAQ:ANNX) Shares Acquired by Northern Trust Corp

Northern Trust Corp boosted its holdings in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 30.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,029,750 shares of the company's stock after purchasing an additional 239,685 shares during the quarter. Northern Trust Corp owned about 0.97% of Annexon worth $5,283,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. E Fund Management Co. Ltd. raised its stake in Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock valued at $79,000 after purchasing an additional 4,086 shares during the period. Wellington Management Group LLP raised its stake in Annexon by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 268,166 shares of the company's stock valued at $1,376,000 after purchasing an additional 4,806 shares during the period. Rhumbline Advisers raised its stake in Annexon by 4.3% during the 4th quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock valued at $728,000 after purchasing an additional 5,854 shares during the period. Bank of New York Mellon Corp raised its stake in Annexon by 2.8% during the 4th quarter. Bank of New York Mellon Corp now owns 230,546 shares of the company's stock valued at $1,183,000 after purchasing an additional 6,226 shares during the period. Finally, MetLife Investment Management LLC raised its stake in Annexon by 17.7% during the 4th quarter. MetLife Investment Management LLC now owns 64,967 shares of the company's stock valued at $333,000 after purchasing an additional 9,755 shares during the period.

Annexon Stock Performance

NASDAQ:ANNX traded up $0.05 during trading hours on Friday, reaching $2.11. The stock had a trading volume of 951,998 shares, compared to its average volume of 1,785,652. Annexon, Inc. has a 52 week low of $1.29 and a 52 week high of $7.85. The company has a 50 day moving average price of $1.86 and a two-hundred day moving average price of $3.50. The stock has a market capitalization of $231.50 million, a PE ratio of -2.01 and a beta of 1.24.

Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.07). Equities research analysts predict that Annexon, Inc. will post -0.96 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Needham & Company LLC decreased their target price on Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reduced their price objective on Annexon from $20.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.